Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018152537 - SEROLOGIC ASSAY FOR SILENT BRAIN ISCHEMIA

Publication Number WO/2018/152537
Publication Date 23.08.2018
International Application No. PCT/US2018/018836
International Filing Date 20.02.2018
IPC
A61B 5/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
A61P 9/10 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 14/435 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/68 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
A61B 5/0042
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
0033Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
004adapted for image acquisition of a particular organ or body part
0042for the brain
A61B 5/0071
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
0059using light, e.g. diagnosis by transillumination, diascopy, fluorescence
0071by measuring fluorescence emission
A61B 5/055
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
055involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/4064
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
40Detecting, measuring or recording for evaluating the nervous system
4058for evaluating the central nervous system
4064Evaluating the brain
A61B 5/4836
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
48Other medical applications
4836Diagnosis combined with treatment in closed-loop systems or methods
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • HINMAN, Jason D.
  • XIAO, Guanxi
Agents
  • CANADY, Karen S.
  • LORTZ, Bradley K.
  • SUNDBY, Suzannah K.
  • HYMAN, Laurence J.
Priority Data
62/461,16120.02.2017US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SEROLOGIC ASSAY FOR SILENT BRAIN ISCHEMIA
(FR) DOSAGE SÉROLOGIQUE POUR ISCHÉMIE CÉRÉBRALE SILENCIEUSE
Abstract
(EN) A method for detection or monitoring status of silent brain ischemia (SBI) and cerebrovascular health. The assay reagents and methods described herein provide a specific indicator of cerebral microvascular disease, enabling clinicians to identify patients at risk for the development of SBI. A method of treating a subject having silent brain ischemia and/or metabolic syndrome comprises administering to the subject aspirin therapy, blood pressure therapy, body weight management, and/or a program of diet and exercise when levels of two or more SBI markers are elevated. Described herein are molecules that are produced by cerebral endothelial cells exposed to chronic vascular risk factors including obesity, hyperlipidemia, hypertension, and glucose intolerance. These stress molecules produced by cerebral endothelial cells are detectable in the serum and serve as diagnostic indicators of brain-specific endothelial cell damage and correlate with MRI indicators of silent stroke and impaired cognitive function.
(FR) Procédé de détection ou de surveillance d'un état d'ischémie cérébrale silencieuse (SBI) et de santé cérébrovasculaire. Les réactifs et procédés de dosage de l'invention fournissent un indicateur spécifique de maladie microvasculaire cérébrale, permettant aux cliniciens d'identifier des patients présentant un risque pour le développement de SBI. Un procédé de traitement d'un sujet ayant une ischémie cérébrale silencieuse et/ou un syndrome métabolique comprend l'administration au sujet d'une thérapie à l'aspirine, d'une thérapie par pression artérielle, d'une gestion de poids corporel et/ou d'un programme de régime et d'exercice lorsque des niveaux d'au moins deux marqueurs SBI sont élevés. L'invention concerne des molécules qui sont produites par des cellules endothéliales cérébrales exposées à des facteurs de risque vasculaire chronique comprenant l'obésité, l'hyperlipidémie, l'hypertension et l'intolérance au glucose. Ces molécules de stress produites par des cellules endothéliales cérébrales sont détectables dans le sérum et servent d'indicateurs de diagnostic de lésions de cellules endothéliales spécifiques du cerveau et sont en corrélation avec des indicateurs d'IRM d'attaque silencieuse et de fonction cognitive altérée.
Latest bibliographic data on file with the International Bureau